Patents by Inventor Yihan Wang

Yihan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190092733
    Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.
    Type: Application
    Filed: December 13, 2016
    Publication date: March 28, 2019
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Xingye Ren
  • Publication number: 20190060292
    Abstract: A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.
    Type: Application
    Filed: February 23, 2017
    Publication date: February 28, 2019
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Publication number: 20190040098
    Abstract: Disclosed are a steroidal compound as shown in formula (I) and a drug composition containing the same, or a crystal form, a pharmaceutically acceptable salt, a hydrate or solvate, a stereoisomer, a prodrug, a metabolite or an isotopic variant thereof. The compound can be used as a CYP17 enzyme inhibitor, and has better pharmacokinetic parameters, which can improve drug concentration of the compound in an animal, thereby improving the efficacy and safety of the drug, and in turn the compound may be applied in the preparation of the drug for treating CYP17 enzyme-related diseases (such as prostate cancer).
    Type: Application
    Filed: December 29, 2016
    Publication date: February 7, 2019
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Xingye Ren
  • Publication number: 20190031656
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: August 6, 2018
    Publication date: January 31, 2019
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Publication number: 20170369446
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Inventors: William C. Shakespeare, Wei-Sheng Huang, David C. Dalgarno, Xiaotian Zhu, R. Mathew Thomas, Yihan Wang, Jiwei Qi, Rajeswari Sundaramoorthi, Dong Zou, Chester A. Metcalf, III, Tomi K. Sawyer, Jan Antoinette C. Romero
  • Patent number: 9834518
    Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: December 5, 2017
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: David C. Dalgarno, Wei-Sheng Huang, William C. Shakespeare, Yihan Wang, Xiaotian Zhu
  • Patent number: 9834521
    Abstract: This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 5, 2017
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Stephan G. Zech, Anna Kohlmann, Feng Li, Yihan Wang, Tianjun Zhou, David C. Dalgarno, William C. Shakespeare, Xiaotian Zhu
  • Patent number: 9834571
    Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: December 5, 2017
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Xiaotian Zhu, Yihan Wang, William C. Shakespeare, Wei-Sheng Huang, David C. Dalgarno
  • Publication number: 20170218000
    Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Patent number: 9573934
    Abstract: The invention features methods and compositions for the synthesis of multimerizing agents.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: February 21, 2017
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Feng Li, Yihan Wang
  • Publication number: 20160376297
    Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: January 25, 2016
    Publication date: December 29, 2016
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, Ranny M. Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Publication number: 20160368917
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: January 21, 2016
    Publication date: December 22, 2016
    Inventors: Dong Zou, Wei-Sheng Huang, Ranny M. Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Publication number: 20160244469
    Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: wherein the variables are as defined herein.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 25, 2016
    Inventors: Xiaotian Zhu, Yihan Wang, William C. Shakespeare, Wei-Sheng Huang, David C. Dalgarno
  • Patent number: 9278971
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 8, 2016
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Dong Zou, Wei-Sheng Huang, R. Mathew Thomas, Jan Antoinette C. Romero, Jiwei Qi, Yihan Wang, Xiaotian Zhu, William C. Shakespeare, Rajeswari Sundaramoorthi, Chester A. Metcalf, III, David C. Dalgarno, Tomi K. Sawyer
  • Patent number: 9273077
    Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use as protein kinase inhibitors.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 1, 2016
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Publication number: 20160024024
    Abstract: This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Stephan G. Zech, Anna Kohlmann, Feng Li, Yihan Wang, Tianjun Zhou, David C. Dalgarno, William C. Shakespeare, Xiaotian Zhu
  • Publication number: 20150225436
    Abstract: The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: April 20, 2015
    Publication date: August 13, 2015
    Applicant: ARIAD PHARMACEUTICALS, INC.
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, Ranny M. Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Patent number: 9090561
    Abstract: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 28, 2015
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Yihan Wang, Xiaotian Zhu, Rajeswari Sundaramoorthi, Wei-Sheng Huang, Dong Zou, R. Mathew Thomas, Jiwei Qi, Jan Antoinette C. Romero, David C. Dalgarno, William C. Shakespeare, Tomi K. Sawyer, Chester A. Metcalf, III
  • Publication number: 20150166591
    Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 18, 2015
    Inventors: Xiaotian Zhu, Yihan Wang, William C. Shakespeare, Wei-Sheng Huang, David C. Dalgarno
  • Publication number: 20150148543
    Abstract: The invention features methods and compositions for the synthesis of multimerizing agents.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 28, 2015
    Inventors: Feng Li, Yihan Wang